Moleculin Biotech Inc logo

MBRX - Moleculin Biotech Inc Share Price

$0.804 0.0  3.1%

Last Trade - 25/09/20

Sector
Healthcare
Size
Micro Cap
Market Cap £38.9m
Enterprise Value £25.8m
Revenue £n/a
Position in Universe 4771st / 6417
Bullish
Bearish
Unlock MBRX Revenue
Momentum
Relative Strength (%)
1m -3.25%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -59.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Moleculin Biotech Inc revenues was not reported. Net loss increased from $5.3M to $11.3M. Higher net loss reflects Gain (loss) from change in fair value of decrease from $2.9M (income) to $1.3M (expense), Depreciation and amortization increase of 1% to $98K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.19.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MBRX Revenue Unlock MBRX Revenue

Net Income

MBRX Net Income Unlock MBRX Revenue

Normalised EPS

MBRX Normalised EPS Unlock MBRX Revenue

PE Ratio Range

MBRX PE Ratio Range Unlock MBRX Revenue

Dividend Yield Range

MBRX Dividend Yield Range Unlock MBRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MBRX EPS Forecasts Unlock MBRX Revenue
Profile Summary

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 28, 2015
Public Since June 2, 2016
No. of Shareholders: 149
No. of Employees: 11
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 61,704,290
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MBRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MBRX
Upcoming Events for MBRX
Frequently Asked Questions for Moleculin Biotech Inc
What is the Moleculin Biotech Inc share price?

As of 25/09/20, shares in Moleculin Biotech Inc are trading at $0.804, giving the company a market capitalisation of £38.9m. This share price information is delayed by 15 minutes.

How has the Moleculin Biotech Inc share price performed this year?

Shares in Moleculin Biotech Inc are currently trading at $0.804 and the price has moved by -29.5% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Moleculin Biotech Inc price has moved by -35.68% over the past year.

What are the analyst and broker recommendations for Moleculin Biotech Inc?

Of the analysts with advisory recommendations for Moleculin Biotech Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Moleculin Biotech Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Moleculin Biotech Inc next release its financial results?

Moleculin Biotech Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Moleculin Biotech Inc dividend yield?

Moleculin Biotech Inc does not currently pay a dividend.

Does Moleculin Biotech Inc pay a dividend?

Moleculin Biotech Inc does not currently pay a dividend.

When does Moleculin Biotech Inc next pay dividends?

Moleculin Biotech Inc does not currently pay a dividend.

How do I buy Moleculin Biotech Inc shares?

To buy shares in Moleculin Biotech Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Moleculin Biotech Inc?

Shares in Moleculin Biotech Inc are currently trading at $0.804, giving the company a market capitalisation of £38.9m.

Where are Moleculin Biotech Inc shares listed? Where are Moleculin Biotech Inc shares listed?

Here are the trading details for Moleculin Biotech Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: MBRX
What kind of share is Moleculin Biotech Inc?

Based on an overall assessment of its quality, value and momentum, Moleculin Biotech Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Moleculin Biotech Inc share price forecast 2020?

Shares in Moleculin Biotech Inc are currently priced at $0.804. At that level they are trading at 0.314% discount to the analyst consensus target price of 0.00.

Analysts covering Moleculin Biotech Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.394 for the next financial year.

How can I tell whether the Moleculin Biotech Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moleculin Biotech Inc. Over the past six months, the relative strength of its shares against the market has been 3.29%. At the current price of $0.804, shares in Moleculin Biotech Inc are trading at -13.1% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Moleculin Biotech Inc PE Ratio?

We were not able to find PE ratio data for Moleculin Biotech Inc.

Who are the key directors of Moleculin Biotech Inc?

We were unable to find the directors for Moleculin Biotech Inc.

Who are the major shareholders of Moleculin Biotech Inc?

Here are the top five shareholders of Moleculin Biotech Inc based on the size of their shareholding:

Sabby Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 6.08% (3.75m shares)
Empery Asset Management, L.P. Investment Advisor/Hedge Fund
Percentage owned: 6.08% (3.75m shares)
Priebe (Waldemar Ph.D.) Individual Investor
Percentage owned: 4.51% (2.78m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.51% (1.55m shares)
AnnaMed, Inc. Corporation
Percentage owned: 2.31% (1.43m shares)
Similar to MBRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.